Who Qualifies as an “Expert” And How Can We Decide Who Is Trustworthy?

Who Qualifies as an “Expert” And How Can We Decide Who Is Trustworthy?

Discerning a real expert from a charlatan is crucial during the COVID-19 pandemic and beyond.

Unsplash

This article is part of the magazine, "The Future of Science In America: The Election Issue," co-published by LeapsMag, the Aspen Institute Science & Society Program, and GOOD.

Expertise is a slippery concept. Who has it, who claims it, and who attributes or yields it to whom is a culturally specific, sociological process. During the COVID-19 pandemic, we have witnessed a remarkable emergence of legitimate and not-so-legitimate scientists publicly claiming or being attributed to have academic expertise in precisely my field: infectious disease epidemiology. From any vantage point, it is clear that charlatans abound out there, garnering TV coverage and hundreds of thousands of Twitter followers based on loud opinions despite flimsy credentials. What is more interesting as an insider is the gradient of expertise beyond these obvious fakers.

A person's expertise is not a fixed attribute; it is a hierarchical trait defined relative to others. Despite my protestations, I am the go-to expert on every aspect of the pandemic to my family. To a reporter, I might do my best to answer a question about the immune response to SARS-CoV-2, noting that I'm not an immunologist. Among other academic scientists, my expertise is more well-defined as a subfield of epidemiology, and within that as a particular area within infectious disease epidemiology. There's a fractal quality to it; as you zoom in on a particular subject, a differentiation of expertise emerges among scientists who, from farther out, appear to be interchangeable.

We all have our scientific domain and are less knowledgeable outside it, of course, and we are often asked to comment on a broad range of topics. But many scientists without a track record in the field have become favorites among university administrators, senior faculty in unrelated fields, policymakers, and science journalists, using institutional prestige or social connections to promote themselves. This phenomenon leads to a distorted representation of science—and of academic scientists—in the public realm.



Trustworthy experts will direct you to others in their field who know more about particular topics, and will tend to be honest about what is and what isn't "in their lane."

Predictably, white male voices have been disproportionately amplified, and men are certainly over-represented in the category of those who use their connections to inappropriately claim expertise. Generally speaking, we are missing women, racial minorities, and global perspectives. This is not only important because it misrepresents who scientists are and reinforces outdated stereotypes that place white men in the Global North at the top of a credibility hierarchy. It also matters because it can promote bad science, and it passes over scientists who can lend nuance to the scientific discourse and give global perspectives on this quintessentially global crisis.

Also at work, in my opinion, are two biases within academia: the conflation of institutional prestige with individual expertise, and the bizarre hierarchy among scientists that attributes greater credibility to those in quantitative fields like physics. Regardless of mathematical expertise or institutional affiliation, lack of experience working with epidemiological data can lead to over-confidence in the deceptively simple mathematical models that we use to understand epidemics, as well as the inappropriate use of uncertain data to inform them. Prominent and vocal scientists from different quantitative fields have misapplied the methods of infectious disease epidemiology during the COVID-19 pandemic so far, creating enormous confusion among policymakers and the public. Early forecasts that predicted the epidemic would be over by now, for example, led to a sense that epidemiological models were all unreliable.

Meanwhile, legitimate scientific uncertainties and differences of opinion, as well as fundamentally different epidemic dynamics arising in diverse global contexts and in different demographic groups, appear in the press as an indistinguishable part of this general chaos. This leads many people to question whether the field has anything worthwhile to contribute, and muddies the facts about COVID-19 policies for reducing transmission that most experts agree on, like wearing masks and avoiding large indoor gatherings.


So how do we distinguish an expert from a charlatan? I believe a willingness to say "I don't know" and to openly describe uncertainties, nuances, and limitations of science are all good signs. Thoughtful engagement with questions and new ideas is also an indication of expertise, as opposed to arrogant bluster or a bullish insistence on a particular policy strategy regardless of context (which is almost always an attempt to hide a lack of depth of understanding). Trustworthy experts will direct you to others in their field who know more about particular topics, and will tend to be honest about what is and what isn't "in their lane." For example, some expertise is quite specific to a given subfield: epidemiologists who study non-infectious conditions or nutrition, for example, use different methods from those of infectious disease experts, because they generally don't need to account for the exponential growth that is inherent to a contagion process.

Academic scientists have a specific, technical contribution to make in containing the COVID-19 pandemic and in communicating research findings as they emerge. But the liminal space between scientists and the public is subject to the same undercurrents of sexism, racism, and opportunism that society and the academy have always suffered from. Although none of the proxies for expertise described above are fool-proof, they are at least indicative of integrity and humility—two traits the world is in dire need of at this moment in history.

[Editor's Note: To read other articles in this special magazine issue, visit the beautifully designed e-reader version.]

Caroline Buckee
Dr. Caroline Buckee is an Associate Professor of Epidemiology and Associate Director of the Centre for Communicable Disease Dynamics at Harvard T.H. Chan School of Public Health. She is a co-founder of the COVID-19 Mobility Data Network, set up to support the use of population behavior data to guide policy makers in their response to the pandemic. Her other work is focused on understanding the mechanisms driving the spread of infectious diseases that impact the most vulnerable populations worldwide, particularly malaria. Before coming to Harvard, Dr. Buckee completed a D.Phil. at the University of Oxford, and Omidyar and Wellcome Trust fellowships at the Santa Fe Institute and the Kenya Medical Research Institute, respectively, where she analyzed malaria parasite evolution and epidemiology. Dr. Buckee’s group uses a range of mathematical models, experimental and genomic data, and “Big Data” from mobile phones and satellites to understand how human pathogens spread and may be controlled.
World First: Drone Delivers Defibrillator That Saves Man in Cardiac Arrest

An autonomous drone carrying an automated external defibrillator travels to a cardiac emergency in Sweden.

Everdrone

Picture this: your medical first responder descends from the sky like a friendly, unmanned starship. Hovering over your door, it drops a device with recorded instructions to help a bystander jumpstart your heart that has stopped. This, after the 911 call but before the ambulance arrives.

This is exactly what happened on Dec. 9, 2021, when a 71-year-old man in Sweden suffered a cardiac arrest while shoveling snow. A passerby, seeing him collapse, called for an ambulance. In just over three minutes, a drone swooped overhead carrying an Automated External Defibrillator (AED). The patient was revived on the spot before the ambulance arrived to rush him to the hospital where he made a full recovery. The revolutionary technology saved his life.

Keep Reading Keep Reading
Eve Glicksman
Eve Glicksman is a freelance writer and editor in Silver Spring, MD. She writes for multiple media outlets and associations on health care, trends, culture, psychology, lifestyle, and travel. To see her work in the Washington Post, WebMD, and U.S. News & World Report, visit eveglicksman.com.
6 Biotech Breakthroughs of 2021 That Missed the Attention They Deserved

A string of the code that comprises a DNA molecule, pictured at Miraikan, the National Museum of Emerging Science and Innovation in Japan.

Miki Yoshihito/Flickr (Creative Commons)

News about COVID-19 continues to relentlessly dominate as Omicron surges around the globe. Yet somehow, during the pandemic’s exhausting twists and turns, progress in other areas of health and biotech has marched on.

In some cases, these innovations have occurred despite a broad reallocation of resources to address the COVID crisis. For other breakthroughs, COVID served as the forcing function, pushing scientists and medical providers to rethink key aspects of healthcare, including how cancer, Alzheimer’s and other diseases are studied, diagnosed and treated. Regardless of why they happened, many of these advances didn’t make the headlines of major media outlets, even when they represented turning points in overcoming our toughest health challenges.

If it bleeds, it leads—and many disturbing stories, such as COVID surges, deserve top billing. Too often, though, mainstream media’s parallel strategy seems to be: if it innovates, it fades to the background. But our breakthroughs are just as critical to understanding the state of the world as our setbacks. I asked six pragmatic yet forward-thinking experts on health and biotech for their perspectives on the most important, but under-appreciated, breakthrough of 2021.

Their descriptions, below, were lightly edited by Leaps.org for style and format.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.